Department of Pathology and Medical Research Institute, Pusan National University School of Medicine, Beomeo-ri, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do, 626-770, Korea.
Lung. 2009 Nov-Dec;187(6):401-11. doi: 10.1007/s00408-009-9181-3. Epub 2009 Oct 1.
Cancer-testis antigens (CTAs) are expressed only in many cancers and limited immunoprivileged sites such as the testis and placenta. Dendritic cells (DCs) and CD8+ T lymphocytes (CTLs) play roles in the immune responses to tumor growth and may affect the prognosis of cancers. This study was designed to investigate the clinicopathologic significance of CTA expression in non-small-cell lung carcinomas (NSCLCs) and its relationship with immune cells. Immunohistochemical staining to CTAs such as MAGE-A3/6 and NY-ESO-1 was performed using paraffin blocks from 132 cases of NSCLCs, including 75 cases of squamous cell carcinoma (SqCC) and 57 cases of adenocarcinoma (AdC), and the results were evaluated to correlate with tumor-infiltrating DCs and CTLs and clinicopathologic features. MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of NSCLCs, respectively. MAGE-A3/6 was expressed more frequently in SqCC than in AdC, but the expression of NY-ESO-1 showed no difference in both types. CTAs revealed a higher expression in male than in female. In advanced stage III, NY-ESO-1-positive patients showed poorer survival than NY-ESO-1-negative patients. Otherwise, the CTA expression did not correlate with clinicopathologic parameters. No relationship was found between DC and CTL infiltration in all NSCLCs. Regarding DC infiltration, the group showing negative expression to CTAs displayed an even higher number of infiltrating DCs than those showing positivity to one or the other or both CTAs. Although the aberrant expression of MAGE-A3/6 and NY-ESO-1 in NSCLC did not directly influence clinical prognostic factors, the higher expression of MAGE-A3/6 in SqCC suggests its value as a potential target for immunotherapy in this type of NSCLC. The inverse relationship between DCs and CTA expression may indicate that CTA-positive tumor cells would be akin to tumor stem cells escaping host immune response.
癌症睾丸抗原(CTAs)仅在许多癌症和有限的免疫豁免部位(如睾丸和胎盘)中表达。树突状细胞(DCs)和 CD8+T 淋巴细胞(CTLs)在肿瘤生长的免疫反应中发挥作用,可能影响癌症的预后。本研究旨在探讨 CTAs 在非小细胞肺癌(NSCLCs)中的表达与免疫细胞的临床病理意义及其相关性。使用来自 132 例 NSCLC 患者的石蜡块进行 CTAs(如 MAGE-A3/6 和 NY-ESO-1)的免疫组织化学染色,包括 75 例鳞状细胞癌(SqCC)和 57 例腺癌(AdC),并评估结果与肿瘤浸润性 DCs 和 CTLs 以及临床病理特征的相关性。MAGE-A3/6 和 NY-ESO-1 在 50.0%(66/132)和 18.2%(24/132)的 NSCLC 中表达。MAGE-A3/6 在 SqCC 中的表达频率高于 AdC,但在两种类型中 NY-ESO-1 的表达没有差异。CTAs 在男性中的表达高于女性。在晚期 III 期,NY-ESO-1 阳性患者的生存情况比 NY-ESO-1 阴性患者差。否则,CTA 的表达与临床病理参数无关。在所有 NSCLC 中,均未发现 DC 和 CTL 浸润之间存在关系。关于 DC 浸润,在 CTAs 表达阴性的组中,浸润性 DC 的数量甚至高于 CTAs 表达阳性的组。尽管 MAGE-A3/6 和 NY-ESO-1 在 NSCLC 中的异常表达并未直接影响临床预后因素,但在 SqCC 中 MAGE-A3/6 的高表达表明其作为这种类型的 NSCLC 免疫治疗潜在靶点的价值。DC 和 CTA 表达之间的反比关系可能表明 CTA 阳性肿瘤细胞类似于逃避宿主免疫反应的肿瘤干细胞。